Skip to content

Clinical study on efficacy and safety of 1064-nm Nd:YAG laser in treating atrophic acne scars

Clinical study on efficacy and safety of 1064-nm Nd:YAG laser in treating atrophic acne scars

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000038978
Enrollment
Unknown
Registered
2020-10-11
Start date
2020-10-13
Completion date
Unknown
Last updated
2021-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acne scars

Interventions

low-time group:low-energy 1064-nm Nd:YAG laser
high-time group:high-energy 1064-nm Nd:YAG laser

Sponsors

Hospital for Skin Diseases (Institute of Dermatology), Chinese Academy of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Healthy men and women aged 18 to 60 years old; 2. Patients with atrophic acne scar and ECCA score >= 130; 3. Patients who can and are willing to comply with all the time and requirements of interview, treatment and evaluation; 4. Patients who can understand and provide written informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with keloid history; 2. Pregnant and lactating women; 3. Patients who are known to be allergic to topical anesthetics; 4. Patients with a recent history of sun exposure; 5. Patients with a history of photosensitization, who have taken orally drugs known to increase photosensitivity in the past 6 months; 6. Patients who took isotretinoin orally within 6 months before the initial treatment or planned to take it during the treatment period; 7. Patients who have received surgical treatment in the past three months include: minimally invasive surgery, filling, injection, plastic surgery or ultraviolet light therapy, intense pulsed light, laser and radio frequency therapy; 8. Patients with previous history of malignant tumor; 9. The researchers think that the subjects have poor compliance or other organic diseases and are not suitable to participate in this clinical study.

Design outcomes

Primary

MeasureTime frame
échelle d’évaluation clinique des cicatrices d’acné, ECCA;

Secondary

MeasureTime frame
investigator global assessment, IGA;Pain Visual Analogue Scale;Patient's satisfaction rate;Side effects;

Countries

China

Contacts

Public ContactLin Tong

Institute of Dermatology, Chinese Academy of Medical Sciences

ddlin@hotmail.com+86 13951902258

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026